In this issue
Insight
It's time to change the way we approach coughs in community pharmacySubscription
Over-the-counter treatments for the common cough need to be brought up to date and improved, especially considering the social and economic implications of the condition.
Correspondence
Pharmacists’ role in optimising the use of medicines in those with learning disabilitiesSubscription
Following on from the response to the Winterbourne View Hospital scandal, where it was discovered many patients suffered serious abuse, the re-evaluation of antipsychotic use in people with learning disabilities has begun, with three separate reports commissioned by NHS England plus a study by Sheehan et al published in The BMJ in September 2015 (
Serious side effect with quinolone antibioticsSubscription
A few weeks ago, I found myself in touch with a woman who was clearly unwell, with a lot of intractable peripheral pain, unable to work and unable to live a normal life. The symptoms had been of sudden onset and she associated them with a course of ciprofloxacin that she had been prescribed. The episode began 30 months before and, at the time of writing, is ongoing, with no signs of improvement. I had never heard of such an effect of ciprofloxacin and was initially somewhat sceptical. ...
CPD article
Bariatric surgery and the effects on drug pharmacokineticsSubscription
Understanding the types of bariatric surgery, their impact on drug pharmacokinetics and specific recommendations for drug regimens following surgery.
Review
Mammalian target of rapamycin (mTOR) inhibitors in solid tumoursSubscription
The phosphatidylinositol-3-kinase /protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway plays an important role in cell proliferation, growth, and angiogenesis.
Current treatments and future targeted treatments for acute myeloid leukaemiaSubscription
While the initial therapy for acute myeloid leukaemia (AML) treatment is relatively standardised, the high incidence of refractory/relapsed disease remains a great challenge. Progress has been made in understanding the pathophysiology of both initial and recurrent disease phases, leading to rigorous pre-clinical studies to identify and selectively target cellular pathways that promote leukaemogenesis. In this article, we discuss the ongoing efforts in overcoming relapsed disease, through ...
